OncoRisk Panel
Comprehensive and Specialized Hereditary Cancer Panel
Overview
Analysis of Inherited Oncogenes
Celemics’ OncoRisk panel is specifically designed to analyze hereditary cancer associated genes. The OncoRisk panel is a hereditary cancer panel that targets 31 well-known oncogenes, leading to a reduction of total sequencing cost compared to whole genome sequencing or whole exome sequencing. Additionally, if the gene of interest does not exist on the panel, it can be added separately through our gene add-on service. This flexible design provides cost-effective sequencing results to every customer.
Comprehensive Analysis of Oncogenes
The panel consists of 31 oncogenes associated with inherited cancer precisely selected from Contract Research Organizations and numerous research studies. Owing to Celemics’ proprietary probe design and manufacture technology, hereditary cancer panel demonstrates industry-leading performance with superior sensitivity and specificity compared to other competitor products in the market.
Robust Bioinformatics System for Large Deletion Analysis
At Celemics, we provide results for large deletion analysis supported by Celemics proprietary bioinformatics analysis system. We also complement this bioinformatics solution with user-friendly customizable solutions, like CNV or any other novel variant analyses.
PN170 CDKN2A CNV plot
- Example of CNV analysis results (CDKN2A) for specific target regions
- Higher sequencing depths in the target regions, enabling accurate CNV analysis
NGS for Homologous Recombination Repair (HRR) Testing
Celemics’ Hereditary Cancer Panel provides information for HRR grade computation to aid precision medicine for tumor treatment with 99.9% and 99.5% specificity for SNV and Indel, respectively. It can also detect all types of mutations with over 95% of sensitivity at 5% VAF.
Example of variants and CNV analysis results
- This example of variant analysis results include AA change, mutation type, total sequencing depth, allele frequency, etc.
| Gene | Mutation Type | Amino Acid Change | Total Depth | REF Depth | ALT Depth | Variant Allele Frequency |
|---|---|---|---|---|---|---|
| APC | SYN | p.S1738S | 1008 | 590 | 415 | 41.17% |
| ATM | Non-SYN | p.D1853N | 417 | 200 | 217 | 52.04% |
| BARD1 | Non-SYN | p.R658C | 829 | 435 | 394 | 47.53% |
| BMPR1A | Non-SYN | p.P2T | 621 | 309 | 311 | 50.08% |
| BRCA1 | SYN | p.S1389S | 802 | 460 | 342 | 42.64% |
| BRCA2 | SYN | p.V2171V | 1026 | 0 | 1026 | 100% |
| BRIP1 | SYN | p.Y1137Y | 844 | 3 | 840 | 99.53% |
| PMS2 | NON-SYN | K541E | 686 | 0 | 646 | 100% |
| PRSS1 | SYN | p.N246N | 921 | 0 | 921 | 100% |
| RAD51D | NON-SYN | p.R53Q | 971 | 0 | 971 | 100% |
Specification
| Gene count* | 31 genes |
|---|---|
| Covered region | Whole CDS |
| Target size | 96 Kb |
| Mutation type | SNV, Indel, CNV, Rearrangement |
| Sample type | Blood (> 50 ng of fragmented DNA), FFPE |
| Platform | All sequencers from Illumina, Thermo Fisher, MGI, PacBio, and Oxford Nanopore |
| Sensitivity | > 95% for all variant types at 5% VAF |
| Specificity | 99.90%(SNV), 99.50%(Indel) |
| Bioinformatics Support | ① Primary Analysis: FASTQ to annotated VCF ② Secondary Analysis: CNV, Large InDel ③ Tertiary Analysis: Clinical interpretation |
Specification - Gene List
| Gene List | APC | ATM | BARD1 | BLM | BMPR1A | BRCA1 | BRCA2 | BRIP1 |
|---|---|---|---|---|---|---|---|---|
| CDH1 | CDK4 | CDKN2A | CHEK2 | EPCAM | MLH1 | MRE11A | MSH2 | |
| MSH6 | MUTYH | NBN | PALB2 | PMS2 | PRSS1 | PTEN | RAD50 | |
| RAD51C | RAD51D | SLX4 | SMAD4 | STK11 | TP53 | VHL |
Related Products
Comprehensive NGS panel for identifying and characterizing the molecular fingerprint for solid tumors with market-leading sensitivity
Highly optimized, user- convenient NGS library preparation kit for all Celemics panels
End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis
Incomparable quality magnetic bead for simple, flexible, and reproducible purification
Comprehensive NGS panel for identifying and characterizing the molecular fingerprint for solid tumors with market-leading sensitivity
Highly optimized, user- convenient NGS library preparation kit for all Celemics panels
End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis
Incomparable quality magnetic bead for simple, flexible, and reproducible purification
Resources
Technical Resources
Safety Data Sheets
If you require the latest MSDS file, please contact us via ‘Contact Us‘.
MSDS_OncoRisk Panel_Illumina
MSDS_OncoRisk Panel_Thermo Fisher
MSDS_OncoRisk Panel_MGI
References
Pathology & Oncology Research
Germline BRCA testing in routine clinical practice: a single-center experience
Nikolényi, A., Dobi, Á., Sántha, D., Kószó, R., Iványi, M., Horváth, E., … & Kahán, Z. (2026). Germline BRCA testing in routine clinical practice: a single-center experience. Pathology and Oncology Research, 32, 1612238.
10.3389/pore.2026.1612238
Scientific Reports
Analytical and clinical validation of CancerMaster, an automated targeted NGS panel, for tumor-only precision oncology
Che, J., Kwon, W. S., Kim, J., Jadamba, E., Han, H. J., Kim, Y., … & Rha, S. Y. (2026). Analytical and clinical validation of CancerMaster, an automated targeted NGS panel, for tumor-only precision oncology. Scientific Reports.
10.1038/s41598-026-37991-0
BMC Cancer
Germline and somatic mutational variants of Tunisian high grade serous ovarian cancer identified by next-generation sequencing
Ammous-Boukhris, N., Abdelmaksoud-Dammak, R., Ben Kridis, W., Ben-Ayed-Guerfali, D., Shtaiwi Abed, A., Guidara, S., … & Mokdad-Gargouri, R. (2025). Germline and somatic mutational variants of Tunisian high grade serous ovarian cancer identified by next-generation sequencing. BMC cancer, 25(1), 1542.
10.1186/s12885-025-14989-x
PloS One
Genetic profiling of inherited colorectal cancer syndromes in Tunisian patients
Abdelmaksoud-Dammak, R., Ammous-Boukhris, N., Saadallah-Kallel, A., Ayed-Guerfali, D. B., Guidara, S., Miladi-Abdennadher, I., … & Mokdad-Gargouri, R. (2025). Genetic profiling of inherited colorectal cancer syndromes in Tunisian patients. Plos one, 20(6), e0326343.
10.1371/journal.pone.0326343